Jay Tibbitts

Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates

Ben‐Quan Shen, Keyang Xu, Luna Liu et al. · Nature Biotechnology · 2012 · 977 citations

Immunoengineering, Immunology, Bioconjugation +8

Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer

Ian E. Krop, Muralidhar Beeram, Shanu Modi et al. · Journal of Clinical Oncology · 2010 · 590 citations

Engineered Thio-Trastuzumab-DM1 Conjugate with an Improved Therapeutic Index to Target Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

Jagath R. Junutula, Kelly M. Flagella, Richard Graham et al. · Clinical Cancer Research · 2010 · 289 citations

Impact of Drug Conjugation on Pharmacokinetics and Tissue Distribution of Anti-STEAP1 Antibody–Drug Conjugates in Rats

C. Andrew Boswell, Eduardo E. Mundo, Crystal Zhang et al. · Bioconjugate Chemistry · 2011 · 200 citations

Nanotherapeutics, Local Pharmacology, Immunology +23

The Effect of Different Linkers on Target Cell Catabolism and Pharmacokinetics/Pharmacodynamics of Trastuzumab Maytansinoid Conjugates

Hans K. Erickson, Gail D. Lewis Phillips, Douglas D. Leipold et al. · Molecular Cancer Therapeutics · 2012 · 191 citations

Vitro Potency, Immunology, Pharmacotherapy +19